14159 capital (GP), LLC
CIK 1317493 · last filed 2012-03-14
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
GHDX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
21ST FLOOR
NEW YORK, NY 10065
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Ocera Therapeutics, Inc. (TZYM) Delisted | 10%+ Owner | 4,609 | — | — | $243.5K | 1 | 2012-03-14 |
| GENOMIC HEALTH INC (GHDX) Delisted | Director | 215,669 | — | — | $4.35M | 15 | 2012-02-29 |
| INCY | Director | 344,064 | $113.31 | $38.99M | -$303.0K | 12 | 2012-01-17 |
| Seagen Inc. (SGEN) Delisted | Director | 323,148 | $228.74 | $73.92M | $2.01M | 5 | 2011-09-08 |
| AUXILIUM PHARMACEUTICALS INC (AUXL) Delisted | 10%+ Owner | 143,568 | — | — | -$430.3K | 3 | 2011-08-03 |
| Ardea Biosciences, Inc./DE (RDEA) Delisted | Director | 93,282 | — | — | $801.3K | 2 | 2011-01-24 |
| RPRX | 10%+ Owner | 38,386 | $64.76 | $2.49M | $49.1K | 1 | 2010-04-28 |
| BCRX | 10%+ Owner | 128,783 | $7.88 | $1.01M | -$200.9K | 1 | 2009-06-01 |
| VIROPHARMA INC (VPHM) Delisted | 10%+ Owner | 187,491 | — | — | -$467.3K | 4 | 2009-05-26 |
| Aceragen, Inc. (IDRA) Delisted | 10%+ Owner | 116 | $7.22 | $838 | -$112.9K | 2 | 2008-07-21 |
| ALLOS THERAPEUTICS INC (ALTH) Delisted | 10%+ Owner | 264,699 | — | — | $309.2K | 3 | 2008-05-27 |
| TAPESTRY PHARMACEUTICALS, INC (TPPH) Delisted | 10%+ Owner | 112,451 | — | — | -$473 | 1 | 2008-04-08 |
| Aceragen, Inc. (IDP) Delisted | 10%+ Owner | 31,708 | — | — | -$101.7K | 3 | 2007-12-07 |
Recent Filings · Page 5 of 6
59 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2008-02-21 | ALLOS THERAPEUTICS INC (ALTH) Delisted | Buy (P) | +24,030 | $152.4K | EDGAR |
| 2008-02-11 | Seagen Inc. (SGEN) Delisted | Buy (P) | +14,649 | $132.1K | EDGAR |
| 2008-01-24 | INCY | Buy (P) | +21 | $223 | EDGAR |
| 2008-01-11 | INCY | Buy (P) | +11,673 | $127.7K | EDGAR |
| 2008-01-10 | VIROPHARMA INC (VPHM) Delisted | Buy (P) | +16,536 | $146.1K | EDGAR |
| 2008-01-04 | Aceragen, Inc. (IDRA) Delisted | Sell (S) | −4,782 | -$62.4K | EDGAR |
| 2007-12-12 | INCY | Buy (P) | +27,538 | $275.1K | EDGAR |
| 2007-12-07 | Aceragen, Inc. (IDP) Delisted | Sell (S) | −4,221 | -$52.0K | EDGAR |
| 2007-12-06 | INCY | Buy (P) | +3,624 | $32.6K | EDGAR |
| 2007-11-21 | INCY | Buy (P) | +17,628 | $144.0K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.